Sacituzumab tirumotecan is an antibody-drug conjugate and TROP2-directed, topoisomerase I inhibitor payload-delivering agent, with a TROP2 EC50 of 2.787 ng/ml, TROP2 Ka of 0.3083 nM, and topoisomerase I IC50 of 0.7 µmol/L. Sacituzumab tirumotecan can be used for the research of metastatic triple-negative breast cancer, and metastatic non-small cell lung cancer[1][2][3].
Molekulargewicht:
157907 (average)
Reinheit:
99.63
CAS Nummer:
[2768350-77-0]
Target-Kategorie:
Antibody-Drug Conjugates (ADCs),TROP2
Anwendungsbeschreibung:
MCE Product type: ADC Related
* Mehrwertsteuer und Versandkosten nicht enthalten. Irrtümer und Preisänderungen vorbehalten